Bharat Biotech's Covaxin safe, immunises for at least 3 months: Lancet

Probability of side effects from vaccine 10-12%, 6x lower than other shots

Results from the phase 2 clinical study published in The Lancet shows that India’s first indigenously developed Covid vaccine to get the regulator’s nod for restricted emergency use — Covaxin — produced durable antibody and T-cell responses three months after vaccination.

Follow-up studies are currently on for six months and 12 months, said the authors of the study.

Moreover, the study noted that neutralising antibody titers produced in vaccinated individuals were twofold than what was observed in the phase 1 study.

The study has been authored by Raches Ella, Krishna Ella of Bharat Biotech and Nivedita Gupta, deputy director general and Balram Bhargava,